AbbVie (ABBV) Increases Buyback by $5B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts ABBV Hot Sheet
Price: $271.36 +1.75%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.6%
Revenue Growth %: +9.7%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.6%
Revenue Growth %: +9.7%
Join SI Premium – FREE
The board of directors of AbbVie Inc. (NYSE: ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program.
Purchases may be made from time to time in management's discretion. The stock repurchase authorization permits shares to be repurchased in open market or private transactions, has no time limit and may be discontinued at any time.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA grants AbbVie's Temab-A two breakthrough therapy designations
- Rezolve Ai gets court approval for capital reduction plan
- Genmab stock surges 11% on positive cancer drug trial data
Create E-mail Alert Related Categories
Corporate News, Hot Buybacks, Stock BuybacksRelated Entities
Twitter, Stock BuybackSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
